The role of saposin C in Gaucher disease

被引:98
作者
Tamargo, Rafael J. [1 ]
Velayati, Arash [1 ]
Goldin, Ehud [1 ]
Sidransky, Ellen [1 ]
机构
[1] NHGRI, Sect Mol Neurogenet, Med Genet Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Prosaposin; Lysosomal storage disorder; Glucocerebrosidase; Modifier; Activator; ACID BETA-GLUCOSIDASE; SPHINGOLIPID ACTIVATOR PROTEINS; ACTIVITY IN-VITRO; METACHROMATIC LEUKODYSTROPHY; PROSAPOSIN GENE; B DEFICIENCY; GLUCOCEREBROSIDASE ACTIVITY; SULFATIDE ACTIVATOR; LYSOSOMAL STORAGE; LIPID-BILAYERS;
D O I
10.1016/j.ymgme.2012.04.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Saposin C is one of four homologous proteins derived from sequential cleavage of the saposin precursor protein, prosaposin. It is an essential activator for glucocerebrosidase, the enzyme deficient in Gaucher disease. Gaucher disease is a rare autosomal recessive lysosomal storage disorder caused by mutations in the GBA gene that exhibits vast phenotypic heterogeneity, despite its designation as a "simple" Mendelian disorder. The observed phenotypic variability has led to a search for disease modifiers that can alter the Gaucher phenotype. The PSAP gene encoding saposin C is a prime candidate modifier for Gaucher disease. In humans, saposin C deficiency due to mutations in PSAP results in a Gaucher-like phenotype, despite normal in vitro glucocerebrosidase activity. Saposin C deficiency has also been shown to modify phenotype in one mouse model of Gaudier disease. The role of saposin C as an activator required for normal glucocerebrosidase function, and the consequences of saposin C deficiency are described, and are being explored as potential modifying factors in patients with Gaucher disease. Published by Elsevier Inc.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 98 条
[21]  
FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339
[22]   THE PRECURSOR OF SULFATIDE ACTIVATOR PROTEIN IS PROCESSED TO 3 DIFFERENT PROTEINS [J].
FURST, W ;
MACHLEIDT, W ;
SANDHOFF, K .
BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1988, 369 (05) :317-328
[23]   ACTIVATOR PROTEINS AND TOPOLOGY OF LYSOSOMAL SPHINGOLIPID CATABOLISM [J].
FURST, W ;
SANDHOFF, K .
BIOCHIMICA ET BIOPHYSICA ACTA, 1992, 1126 (01) :1-16
[24]  
Futerman A.H., 2006, GAUCHER DIS
[25]   Divergent phenotypes in Gaucher disease implicate the role of modifiers [J].
Goker-Alpan, O ;
Hruska, KS ;
Orvisky, E ;
Kishnani, PS ;
Stubblefield, BK ;
Schiffmann, R ;
Sidransky, E .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (06)
[26]   Phenotypic continuum in neuronopathic Gaucher disease: An intermediate phenotype between type 2 and type 3 [J].
Goker-Alpan, O ;
Schiffmann, R ;
Park, JK ;
Stubblefield, BK ;
Tayebi, N ;
Sidransky, E .
JOURNAL OF PEDIATRICS, 2003, 143 (02) :273-276
[27]   Molecular chaperones in protein folding and proteostasis [J].
Hartl, F. Ulrich ;
Bracher, Andreas ;
Hayer-Hartl, Manajit .
NATURE, 2011, 475 (7356) :324-332
[28]   SECRETION OF SPHINGOLIPID HYDROLASE ACTIVATOR PRECURSOR, PROSAPOSIN [J].
HINENO, T ;
SANO, A ;
KONDOH, K ;
UENO, S ;
KAKIMOTO, Y ;
YOSHIDA, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 176 (02) :668-674
[29]  
Hiraiwa M, 1999, GLIA, V26, P353, DOI 10.1002/(SICI)1098-1136(199906)26:4<353::AID-GLIA9>3.3.CO
[30]  
2-7